Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Under the agreement, Searchlight Pharma (“Searchlight”), Apotex's Specialty Pharma Division, will pursue marketing authorization for Qutenza® and market and distribute Qutenza® in Canada upon regulatory approval. Grünenthal will receive an upfront payment in addition to regulatory milestone payments and royalties.
Grünenthal acquired the global rights to Qutenza® in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and continues to generate additional value by integrating the acquired brands into Grünenthal's infrastructure, creating synergies throughout manufacturing, logistics, and commercial activities.
“We have continuously developed Qutenza® to expand its footprint and reach more patients in need – most notably through a relaunch and label extension in the US,” says Jan Adams, Chief Commercial Officer (CCO) at Grünenthal. “Apotex's exceptional commercial capabilities make them the ideal partner for us to tap into the Canadian market, one of the largest pharmaceutical markets in the world. We look forward to serving Canadian patients with this non-systemic, non-opioid treatment option and moving closer to our vision of a world free of pain.”
This agreement further reinforces Apotex's dedication to meeting the needs of patients with innovative solutions and expands Apotex's global portfolio of more than 550 pharmaceutical and consumer health products.
“Licensing the Canadian rights to Qutenza® enables us to improve the lives of Canadians by increasing the options for advanced pain management, specifically by bringing to Canada a differentiated and novel agent for the treatment of neuropathic pain that is already commercialized in the EU and US markets,” said Mark Nawacki, President of Searchlight. “This agreement demonstrates our continued momentum along our Journey of Health growth strategy and our dedication to enhancing patient care.”
Contacts
Florian DieckmannHead Global Corporate AffairsGrünenthal
Tel:+49 241 569-2555Florian.Dieckmann@grunenthal.comMedia contactApotex
media@apotex.comAbout Qutenza®
In Europe, Qutenza® is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit www.grunenthalhealth.com.
Qutenza® (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at www.qutenza.com.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the US Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group | Instagram: grunenthal
About Apotex and Searchlight Pharma
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Searchlight Pharma, the specialty pharma division of Apotex, executes best-in-class search, acquisition, and focused development of innovative and unique specialty healthcare products, with a core of its promoted products focused on women's health, dermatology, allergy, pain management and hospital specialty markets.
Learn more about us at www.apotex.com and at www.searchlightpharma.com.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
GITEX EUROPE 2025 - Reigniting an Open, Bold & Collaborative European Digital Economy Amidst €200bn AI Ambitions15.4.2025 13:00:56 CEST | Press Release
Innovation, investment and government leaders set to meet at GITEX EUROPE x Ai Everything, 21-23 May, Messe Berlin, the continent’s largest inaugural tech, startup and digital investment event
“Relaxing rocks”: Spectacular naming of Mein Schiff Relax with Robbie Williams10.4.2025 16:41:15 CEST | Press Release
For the first time, guests of three ships in the fleet were able to experience the festive moment together The staging of the naming ceremony, a choir and many technical refinements such as lasers, video mapping and LED wristbands ensured “endless moments” International superstar and feel-good ambassador of Mein Schiff Relax Robbie Williams wows over 12,000 people with his concert Three ships and a naming ceremony: unique and unprecedented fleet get-together – Mein Schiff 5, Mein Schiff 7 and Mein Schiff Relax in the port of Málaga
Germany’s new Migration Museum: This is What it Will Look Like10.4.2025 11:30:00 CEST | Pressmeddelande
Cologne, April 10, 2025 – Cologne is getting ready to welcome a new attraction in 2029: The Museum Selma will showcase Germany's past and present as a society shaped by immigration. The exhibition, based on 150,000 artifacts and testimonies witnessing to the history of migration in Germany, will have its home in a former industrial hall, promising visitors a unique free-flow experience. Behind this all is an organization started by migrants themselves. The museum is being developed with public funding of 44.26 million euro. ATELIER BRÜCKNER will take the lead on the project’s architectural and exhibition design, with a particular focus on sustainability.
Ny utmärkelse som TOP-researrangör3.4.2025 15:09:16 CEST | Pressmeddelande
Förnyad certifiering lagom till 15-årsjubileet för företaget
Financial Year 2024: Weleda Achieves Record Turnover and Significantly Improves Profitability2.4.2025 11:30:00 CEST | Pressmeddelande
Turnover increased by 8.3% to EUR 456.2 million. Operating profit (EBIT excluding special effects) more than doubled from EUR 13.4 million to EUR 28.3 million. Both business units – Natural Cosmetics and Pharmaceuticals – delivered strong growth worldwide. Strategic growth drivers: internationalisation, digitalisation, innovation, and premiumisation. CEO Tina Müller: “2024 was a year of renewal for Weleda – and a very strong year for us economically. Our strategy of growth with responsibility is working.” CEO Tina Müller: “We have once again started the new financial year with strong momentum. We will continue our sustainable growth path with many innovations.”
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom